CO6160234A2 - Nuevos compuestos ciclicos fusionados que presentan una accion moduladora de la funcion del recptor gpr40 - Google Patents
Nuevos compuestos ciclicos fusionados que presentan una accion moduladora de la funcion del recptor gpr40Info
- Publication number
- CO6160234A2 CO6160234A2 CO09006709A CO09006709A CO6160234A2 CO 6160234 A2 CO6160234 A2 CO 6160234A2 CO 09006709 A CO09006709 A CO 09006709A CO 09006709 A CO09006709 A CO 09006709A CO 6160234 A2 CO6160234 A2 CO 6160234A2
- Authority
- CO
- Colombia
- Prior art keywords
- optionally substituted
- group
- compound according
- ring
- recruitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
1.- Un compuesto representado por la fórmula (I):caracterizado porque R1 es R6-SO2- (donde R6 es un sustituyente) o un grupo 1,1-dioxidotetrahidrotiopiranilo opcionalmente sustituido; X es un enlace o un grupo hidrocarbonado divalente; R2 y R3 son iguales o diferentes y cada uno es un átomo de hidrógeno, un átomo de halógeno, un grupo hidrocarbonado opcionalmente sustituido o un grupo hidroxi opcionalmente sustituido; R4 y R5 son iguales o diferentes y cada uno es un grupo alquilo C1-6 opcionalmente sustituido con grupo(s) hidroxi; el anillo A es un anillo bencénico que opcionalmente presenta además sustituyente(s) seleccionados de un átomo de halógeno, un grupo hidrocarbonado opcionalmente sustituido, un grupo hidroxi opcionalmente sustituido y un grupo amino opcionalmente sustituido; el anillo B es un anillo de 5 a 7 miembros; Y es un enlace o CH2; y R es un grupo hidroxi opcionalmente sustituido, o una sal del mismo. 2.- El compuesto de conformidad con la reivindicación 1, caracterizado porque R1 es R6-SO2- (donde R6 es un sustituyente). 3.- El compuesto de conformidad con la reivindicación 2, caracterizado porque R6 es un grupo alquilo C1-6.4.- El compuesto de conformidad con la reivindicación 1, caracterizado porque X es un grupo alquileno C1-6.5.- El compuesto de conformidad con la reivindicación 1, caracterizado porque R2 y R3 son iguales o diferentes y cada uno es un átomo de hidrógeno, un átomo de halógeno o un grupo alquilo C1-6.6.- El compuesto de conformidad con la reivindicación 1, caracterizado porque R4 y R5 son iguales o diferentes y cada uno es un grupo alquilo C1-6. 7.- El compuesto de conformidad con la reivindicación 1, caracterizado porque el anillo A es un anillo bencénico no sustituido.8.- El compuesto de conformidad con la reivindicación 1, caracterizado porque el anillo B es tetrahidrofurano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006177099 | 2006-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6160234A2 true CO6160234A2 (es) | 2010-05-20 |
Family
ID=38656568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09006709A CO6160234A2 (es) | 2006-06-27 | 2009-01-26 | Nuevos compuestos ciclicos fusionados que presentan una accion moduladora de la funcion del recptor gpr40 |
Country Status (37)
Country | Link |
---|---|
US (5) | US7732626B2 (es) |
EP (4) | EP2248812B1 (es) |
JP (3) | JP4401428B2 (es) |
KR (1) | KR101058772B1 (es) |
CN (4) | CN103070854A (es) |
AR (1) | AR061644A1 (es) |
AT (1) | ATE543815T1 (es) |
AU (1) | AU2007265966B2 (es) |
BR (1) | BRPI0713378A8 (es) |
CA (2) | CA2656003C (es) |
CL (1) | CL2007001873A1 (es) |
CO (1) | CO6160234A2 (es) |
CR (1) | CR10564A (es) |
CY (2) | CY1112705T1 (es) |
DK (2) | DK2248812T5 (es) |
ES (2) | ES2450081T3 (es) |
GE (1) | GEP20115359B (es) |
HK (1) | HK1131126A1 (es) |
HR (2) | HRP20120333T1 (es) |
IL (1) | IL195947A (es) |
JO (1) | JO2969B1 (es) |
MA (1) | MA30537B1 (es) |
ME (1) | ME00535B (es) |
MX (1) | MX2008016274A (es) |
MY (1) | MY154798A (es) |
NO (1) | NO20090235L (es) |
NZ (1) | NZ574038A (es) |
PE (1) | PE20080993A1 (es) |
PL (2) | PL2041123T3 (es) |
PT (2) | PT2041123E (es) |
RS (2) | RS53230B (es) |
RU (1) | RU2444521C2 (es) |
SI (2) | SI2041123T1 (es) |
TW (1) | TWI354668B (es) |
UA (1) | UA95296C2 (es) |
WO (1) | WO2008001931A2 (es) |
ZA (1) | ZA200900154B (es) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009048527A1 (en) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
JP2011515341A (ja) * | 2008-03-06 | 2011-05-19 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体 |
WO2009117421A2 (en) * | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
JP2012503595A (ja) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
TW201014850A (en) | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
EP2371826A4 (en) | 2008-12-29 | 2012-06-27 | Takeda Pharmaceutical | NEW CONNECTION WITH CONDENSED RINGS AND ITS USE |
WO2010087467A1 (en) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Delta-5-desaturase inhibitors |
KR20120022801A (ko) | 2009-04-22 | 2012-03-12 | 아스텔라스세이야쿠 가부시키가이샤 | 카르복실산 화합물 |
US20120172351A1 (en) | 2009-06-09 | 2012-07-05 | Nobuyuki Negoro | Novel fused cyclic compound and use thereof |
SG178062A1 (en) | 2009-07-28 | 2012-03-29 | Takeda Pharmaceutical | Tablet |
WO2011052756A1 (ja) | 2009-10-30 | 2011-05-05 | 持田製薬株式会社 | 新規3-ヒドロキシ-5-アリールイソキサゾール誘導体 |
JP5002077B2 (ja) | 2009-12-25 | 2012-08-15 | 持田製薬株式会社 | 新規3−ヒドロキシ−5−アリールイソチアゾール誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN103025716B (zh) | 2010-04-27 | 2014-12-24 | 武田药品工业株式会社 | 二环化合物衍生物及其作为acc抑制剂的用途 |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
EA022094B1 (ru) | 2010-06-16 | 2015-10-30 | Такеда Фармасьютикал Компани Лимитед | Кристаллическая форма амидного соединения |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
JP5816626B2 (ja) | 2010-09-17 | 2015-11-18 | 武田薬品工業株式会社 | 糖尿病治療剤 |
JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
BR112013013417A2 (pt) | 2010-11-30 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal |
EP2646425B1 (en) | 2010-12-01 | 2015-06-10 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome |
EA201391180A1 (ru) * | 2011-02-17 | 2014-01-30 | Такеда Фармасьютикал Компани Лимитед | Способ получения оптически активных производных дигидробензофурана |
WO2012136221A1 (en) | 2011-04-08 | 2012-10-11 | Syddansk Universitet | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
JP5420796B2 (ja) | 2011-04-27 | 2014-02-19 | 持田製薬株式会社 | 新規3−ヒドロキシイソチアゾール1−オキシド誘導体 |
AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN103012343B (zh) * | 2011-09-26 | 2015-04-08 | 上海恒瑞医药有限公司 | 稠合环类衍生物、其制备方法及其在医药上的应用 |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
JP6129850B2 (ja) | 2012-01-12 | 2017-05-17 | 武田薬品工業株式会社 | Mch受容体拮抗剤としてのベンゾイミダゾール誘導体 |
CN103429581B (zh) * | 2012-01-12 | 2015-08-26 | 江苏恒瑞医药股份有限公司 | 多环类衍生物、其制备方法及其在医药上的应用 |
GB2498968A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist |
WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
JP6095580B2 (ja) | 2012-02-13 | 2017-03-15 | 武田薬品工業株式会社 | 芳香環化合物 |
CN104254322B (zh) | 2012-02-15 | 2017-06-13 | 武田药品工业株式会社 | 片剂 |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
TW201341356A (zh) * | 2012-02-28 | 2013-10-16 | 皮拉馬爾企業有限公司 | 作為gpr促效劑之苯基烷酸衍生物 |
US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
EP2832725A4 (en) | 2012-03-29 | 2015-11-25 | Takeda Pharmaceutical | AROMATIC RING CONNECTION |
US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
US9505772B2 (en) | 2012-05-10 | 2016-11-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
EP2848621A4 (en) | 2012-05-10 | 2016-06-01 | Takeda Pharmaceutical | AROMATIC CYCLIC COMPOUND |
TWI580444B (zh) | 2012-06-05 | 2017-05-01 | 武田藥品工業股份有限公司 | 固態製劑 |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
JP2015127299A (ja) | 2012-07-19 | 2015-07-09 | 武田薬品工業株式会社 | 固形製剤 |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
SI2894151T1 (sl) | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
EP2920165B1 (en) | 2012-11-16 | 2016-09-28 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
EP2925748B1 (en) | 2012-11-28 | 2017-01-11 | Boehringer Ingelheim International GmbH | Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases |
WO2014086712A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
WO2014122067A1 (en) | 2013-02-06 | 2014-08-14 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
AU2014221489B2 (en) * | 2013-02-28 | 2018-03-08 | Tiumbio Co., Ltd. | Tricyclic compound and use thereof |
CN103145663B (zh) * | 2013-03-01 | 2016-03-23 | 上海高准医药有限公司 | (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物,其制备方法及其在医药上的应用 |
JP6247697B2 (ja) | 2013-03-14 | 2017-12-13 | 武田薬品工業株式会社 | スピロアゼチジンイソキサゾール誘導体及びそのsstr5アンタゴニストとしての使用 |
CN104059039B (zh) * | 2013-03-22 | 2017-03-15 | 正大天晴药业集团股份有限公司 | 具有gpr40受体功能调节作用的稠环化合物 |
WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
AR096041A1 (es) | 2013-04-17 | 2015-12-02 | Piramal Entpr Ltd | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg |
CN104870429B (zh) * | 2013-05-22 | 2017-05-03 | 四川海思科制药有限公司 | 苯并呋喃衍生物、其制备方法及其在医药上的应用 |
CN104250238B (zh) * | 2013-06-25 | 2017-12-26 | 南京圣和药业股份有限公司 | Gpr40激动剂及其应用 |
CN104250239B (zh) * | 2013-06-29 | 2016-09-07 | 山东轩竹医药科技有限公司 | 芳香多环羧酸衍生物 |
WO2015000412A1 (zh) * | 2013-07-02 | 2015-01-08 | 四川海思科制药有限公司 | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 |
EP3019487A1 (en) | 2013-07-09 | 2016-05-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
DK3031799T3 (en) | 2013-08-09 | 2018-05-28 | Takeda Pharmaceuticals Co | AROMATIC CONNECTION |
CN104370864B (zh) * | 2013-08-14 | 2016-04-13 | 成都苑东生物制药股份有限公司 | 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法 |
WO2015032328A1 (zh) * | 2013-09-03 | 2015-03-12 | 四川海思科制药有限公司 | 茚满衍生物及其制备方法和在医药上的应用 |
JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104592211B (zh) * | 2013-10-31 | 2018-10-16 | 广东东阳光药业有限公司 | 联苯类化合物及其用途 |
AP2016009176A0 (en) | 2013-11-14 | 2016-04-30 | Cadila Healthcare Ltd | Novel heterocyclic compounds |
EP3068768B1 (en) | 2013-11-15 | 2019-07-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104650055A (zh) * | 2013-11-22 | 2015-05-27 | 山东轩竹医药科技有限公司 | 芳香多环羧酸衍生物 |
WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN105001212B (zh) * | 2014-04-16 | 2018-01-16 | 江苏柯菲平医药股份有限公司 | 稠环化合物及其制备方法和应用 |
WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
EP3177287B1 (en) | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
CN104193731B (zh) * | 2014-08-27 | 2017-03-15 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
CN104177320B (zh) * | 2014-08-27 | 2016-03-02 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
RU2680248C1 (ru) | 2014-10-17 | 2019-02-19 | Хюндай Фарм Ко., Лтд. | Комбинация, содержащая новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты и другой активный ингредиент, для активирования фермента рецептора g-белка 40 |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
CN105418563B (zh) * | 2015-12-28 | 2017-11-10 | 山东大学 | Tak‑875类似物及其制备方法与应用 |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN110312714B (zh) | 2017-01-26 | 2022-12-09 | 勃林格殷格翰国际有限公司 | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 |
WO2018138028A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
JP7049353B2 (ja) | 2017-02-08 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
CN110719903A (zh) | 2017-03-31 | 2020-01-21 | 武田药品工业株式会社 | 芳族环化合物 |
AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
WO2019099315A1 (en) | 2017-11-16 | 2019-05-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
JP7289305B2 (ja) | 2018-01-08 | 2023-06-09 | セロン ファーマ エス.アー. | Gpr40アゴニストとしての3-フェニル-4-ヘキシン酸誘導体 |
MX2020008404A (es) | 2018-02-13 | 2020-09-25 | Gilead Sciences Inc | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). |
CN110294744A (zh) * | 2018-03-21 | 2019-10-01 | 中国医学科学院药物研究所 | Gpr40受体激动剂、其制法和其药物组合物与用途 |
KR20210008834A (ko) | 2018-03-23 | 2021-01-25 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
AU2019301811B2 (en) | 2018-07-13 | 2022-05-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP6773938B2 (ja) | 2018-08-27 | 2020-10-21 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
JP2022503793A (ja) | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
EP3856339A1 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
JPWO2020166662A1 (ja) * | 2019-02-13 | 2021-12-09 | 株式会社ジェクスヴァル | 骨疾患の予防または治療用の医薬組成物 |
WO2022034664A1 (ja) | 2020-08-12 | 2022-02-17 | 株式会社ジェクスヴァル | 骨疾患の予防または治療用の医薬組成物 |
IL296219A (en) | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Weekly doses of gip receptor agonist peptides and their uses |
AU2021241257A1 (en) | 2020-03-25 | 2022-10-13 | Takeda Pharmaceutical Company Limited | QD dosing of GIP receptor agonist peptide compounds and uses thereof |
WO2022133111A1 (en) * | 2020-12-16 | 2022-06-23 | Regents Of The University Of Minnesota | Cubanyl biguanide compounds |
AU2022272251A1 (en) | 2021-05-13 | 2023-11-16 | Carmot Therapeutics Inc. | Modulators of g-protein coupled receptors |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
US5489586A (en) | 1994-03-07 | 1996-02-06 | Warner-Lambert Company | Method for treating inflammatory disease in humans |
US5612330A (en) | 1994-03-07 | 1997-03-18 | Warner-Lambert Company | Methods for inhibiting and controlling viral growth |
WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
RU6023U1 (ru) | 1997-01-20 | 1998-02-16 | АО "Автоэлектроника" | Устройство управления для экономайзера принудительного холостого хода |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
WO1999022735A1 (en) | 1997-10-30 | 1999-05-14 | Merck & Co., Inc. | Somatostatin agonists |
WO2000064876A1 (en) | 1999-04-28 | 2000-11-02 | Aventis Pharma Deutschland Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
RU11297U1 (ru) | 1999-06-16 | 1999-09-16 | Курзанов Евгений Владимирович | Установка для выборочного измерения производительности нефтяных источников при групповом учете |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
DE60024120T2 (de) | 1999-08-26 | 2006-07-27 | Aventis Pharmaceuticals Inc. | Substituierte (aminoiminomethyl oder aminomethyl) dihydrobenzofurane und benozopyrane |
AU7556800A (en) | 1999-10-07 | 2001-05-10 | Tadeka Chemical Industries, Ltd. | Amine derivatives |
MY141468A (en) | 1999-11-10 | 2010-04-30 | Takeda Pharmaceutical | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
CA2395414A1 (en) * | 1999-12-24 | 2001-07-05 | Kyowa Hakko Kogyo Co., Ltd | Condensed purine derivative |
US6930185B2 (en) | 2000-04-28 | 2005-08-16 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
WO2001087834A1 (fr) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
RU2340611C2 (ru) | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
DE60128709T2 (de) | 2000-09-15 | 2007-12-27 | Vertex Pharmaceuticals Inc., Cambridge | Triazol-verbindungen als protein-kinase-inhibitoren |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001297625A1 (en) | 2000-12-21 | 2002-09-12 | Bristol-Myers Squibb Company | Nucleic acid molecules and polypeptides for a human cation channel polypeptide |
KR100947185B1 (ko) | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
DE60216823T2 (de) | 2001-03-30 | 2007-10-04 | Pfizer Products Inc., Groton | Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren. |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
TW522326B (en) * | 2001-08-03 | 2003-03-01 | Inventec Corp | Real-time data customer service system and method thereof |
US6701066B2 (en) * | 2001-10-11 | 2004-03-02 | Micron Technology, Inc. | Delivery of solid chemical precursors |
US20050245571A1 (en) | 2001-10-19 | 2005-11-03 | Hidenori Abe | Amine derivative |
JP4166024B2 (ja) | 2002-03-07 | 2008-10-15 | 独立行政法人科学技術振興機構 | 2環式化合物およびその製造方法 |
PT1501815E (pt) | 2002-04-26 | 2007-01-31 | Hoffmann La Roche | Fenilacetamidas substituídas e a sua utilização como activadores de glicocinase |
WO2004011469A1 (ja) * | 2002-07-26 | 2004-02-05 | Kyowa Hakko Kogyo Co., Ltd. | 細胞分化誘導剤 |
EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
US20070105959A1 (en) * | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
EP1630152A4 (en) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
PE20050444A1 (es) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
RU2353617C2 (ru) | 2003-10-31 | 2009-04-27 | Такеда Фармасьютикал Компани Лимитед | Производные пиридина в качестве ингибиторов дипептидилпептидазы iv |
US7834013B2 (en) | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
JP4074616B2 (ja) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 |
WO2005063725A1 (ja) * | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
US7786165B2 (en) * | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
EP2253315A1 (en) * | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
JP3689711B1 (ja) | 2004-12-24 | 2005-08-31 | 極東鋼弦コンクリート振興株式会社 | 真空グラウト注入方法 |
TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
US20090088419A1 (en) | 2005-02-25 | 2009-04-02 | Takeda Pharmaceutical Company Limited | Pyridyl acetic acid compounds |
TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
PE20080344A1 (es) * | 2006-06-27 | 2008-06-09 | Sanofi Aventis | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 |
PE20080212A1 (es) * | 2006-06-27 | 2008-04-25 | Sanofi Aventis | Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1) |
-
2007
- 2007-06-26 ME MEP-2008-901A patent/ME00535B/me unknown
- 2007-06-26 MX MX2008016274A patent/MX2008016274A/es active IP Right Grant
- 2007-06-26 PT PT07767983T patent/PT2041123E/pt unknown
- 2007-06-26 AT AT07767983T patent/ATE543815T1/de active
- 2007-06-26 RU RU2009102515/04A patent/RU2444521C2/ru active
- 2007-06-26 PL PL07767983T patent/PL2041123T3/pl unknown
- 2007-06-26 CN CN2012105303389A patent/CN103070854A/zh active Pending
- 2007-06-26 KR KR1020097001696A patent/KR101058772B1/ko not_active IP Right Cessation
- 2007-06-26 ES ES10172951.5T patent/ES2450081T3/es active Active
- 2007-06-26 GE GEAP200711077A patent/GEP20115359B/en unknown
- 2007-06-26 JP JP2008554357A patent/JP4401428B2/ja not_active Expired - Fee Related
- 2007-06-26 EP EP10172951.5A patent/EP2248812B1/en active Active
- 2007-06-26 ES ES07767983T patent/ES2379661T3/es active Active
- 2007-06-26 AR ARP070102823A patent/AR061644A1/es unknown
- 2007-06-26 RS RS20140115A patent/RS53230B/en unknown
- 2007-06-26 CA CA2656003A patent/CA2656003C/en active Active
- 2007-06-26 EP EP11194016A patent/EP2431367A3/en not_active Withdrawn
- 2007-06-26 US US12/308,699 patent/US7732626B2/en active Active
- 2007-06-26 SI SI200730892T patent/SI2041123T1/sl unknown
- 2007-06-26 CN CN2007800320224A patent/CN101616913B/zh active Active
- 2007-06-26 AU AU2007265966A patent/AU2007265966B2/en not_active Ceased
- 2007-06-26 EP EP13190005.2A patent/EP2743268A3/en not_active Withdrawn
- 2007-06-26 WO PCT/JP2007/063208 patent/WO2008001931A2/en active Application Filing
- 2007-06-26 RS RS20120169A patent/RS52307B/en unknown
- 2007-06-26 MY MYPI20085345A patent/MY154798A/en unknown
- 2007-06-26 UA UAA200900604A patent/UA95296C2/uk unknown
- 2007-06-26 CA CA2838448A patent/CA2838448A1/en not_active Abandoned
- 2007-06-26 BR BRPI0713378A patent/BRPI0713378A8/pt not_active IP Right Cessation
- 2007-06-26 PE PE2007000827A patent/PE20080993A1/es not_active Application Discontinuation
- 2007-06-26 DK DK10172951.5T patent/DK2248812T5/da active
- 2007-06-26 TW TW096122999A patent/TWI354668B/zh not_active IP Right Cessation
- 2007-06-26 JO JO2007260A patent/JO2969B1/en active
- 2007-06-26 CL CL2007001873A patent/CL2007001873A1/es unknown
- 2007-06-26 PT PT101729515T patent/PT2248812E/pt unknown
- 2007-06-26 SI SI200731426T patent/SI2248812T1/sl unknown
- 2007-06-26 ZA ZA200900154A patent/ZA200900154B/xx unknown
- 2007-06-26 PL PL10172951T patent/PL2248812T3/pl unknown
- 2007-06-26 EP EP07767983A patent/EP2041123B9/en active Active
- 2007-06-26 CN CN2012105303764A patent/CN103083307A/zh active Pending
- 2007-06-26 DK DK07767983.5T patent/DK2041123T3/da active
- 2007-06-26 NZ NZ574038A patent/NZ574038A/en not_active IP Right Cessation
- 2007-06-26 CN CN201210241482.0A patent/CN102731451B/zh active Active
-
2008
- 2008-12-15 IL IL195947A patent/IL195947A/en not_active IP Right Cessation
- 2008-12-30 MA MA31524A patent/MA30537B1/fr unknown
-
2009
- 2009-01-14 NO NO20090235A patent/NO20090235L/no unknown
- 2009-01-16 CR CR10564A patent/CR10564A/es not_active IP Right Cessation
- 2009-01-26 CO CO09006709A patent/CO6160234A2/es unknown
- 2009-07-16 JP JP2009168271A patent/JP4917634B2/ja not_active Expired - Fee Related
- 2009-09-30 HK HK09109075.0A patent/HK1131126A1/xx not_active IP Right Cessation
-
2010
- 2010-03-17 US US12/659,695 patent/US8088821B2/en not_active Expired - Fee Related
-
2011
- 2011-11-02 US US13/287,639 patent/US8492430B2/en not_active Expired - Fee Related
- 2011-12-08 JP JP2011269300A patent/JP5409757B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-16 HR HRP20120333TT patent/HRP20120333T1/hr unknown
- 2012-04-25 CY CY20121100396T patent/CY1112705T1/el unknown
-
2013
- 2013-06-05 US US13/910,374 patent/US8598226B2/en not_active Expired - Fee Related
- 2013-10-25 US US14/063,100 patent/US20140080891A1/en not_active Abandoned
-
2014
- 2014-03-05 HR HRP20140201TT patent/HRP20140201T1/hr unknown
- 2014-03-18 CY CY20141100213T patent/CY1114978T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160234A2 (es) | Nuevos compuestos ciclicos fusionados que presentan una accion moduladora de la funcion del recptor gpr40 | |
CU23926B1 (es) | Derivado de oxopirazina y herbicida | |
DOP2011000061A (es) | Compuestos de pirrol | |
CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
GT200500286A (es) | Analogos de anilino-pirimidina | |
CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
CR8264A (es) | Derivados de malonamida bloqueadores de la actividad gamma-secretase | |
CO5650243A2 (es) | Modulador del receptor canabinoide | |
AR057914A1 (es) | Compuestos organicos de azufre y su uso | |
TW200637559A (en) | 3-propenylcefem derivative | |
CY1112914T1 (el) | Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης | |
AR055144A1 (es) | Inhibidor de secrecion acida | |
CO6190620A2 (es) | Triazoles biciclicos como moduladores de la proteina cinasa | |
ATE526321T1 (de) | Neue epoxidverbindung, alkalisch entwickelbare harzzusammensetzung und alkalisch entwickelbare lichtempfindliche harzzusammensetzung | |
AR058776A1 (es) | Compuesto de piridina condensado | |
DOP2010000219A (es) | Derivados de ftalazinona | |
AR049784A1 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
AR065795A1 (es) | Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros. | |
AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
RS52900B (en) | Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them | |
RU2010153107A (ru) | Композиции флуоресцентного отбеливающего агента | |
EA201000881A1 (ru) | Пиридилметил-сульфонамидные соединения | |
AR060379A1 (es) | Compuesto y composicion herbicida | |
AR055420A1 (es) | Derivados de pirimidina sustituidos |